Referencias

1. Tanner JM, Isrealsohn WJ. Parent-child correlations for body measurements of children between the ages of one month and seven years. Ann Hum Genet 1963;26:245.

2. Daughaday WH. Endocrine control of growth. New York: Elsevier, 1981.

3. Tanner JM. A history of the study of human growth. Cambridge: Cambridge University Press, 1981.

4. Polani PE. Chromosome annomalies. Ann Rev Med 1964;93:15.

5. Garn SM, Clark DC. Nutrition, growth, development and maturation. Findings from the ten state nutrition survey of 1968-1970. Pediatrics 1975;56:306-314.

6. Ramos-Galván R. Somatometría pediátrica. Arch Invest Med (Mex) 1975;6 (Supl 1).

7. Moreno-Esteban B, Tresguerres-Hernández JAF. Retrasos del crecimiento. Madrid: Editorial Díaz de Santos, 1991:8.

8. Nishimura-Megura E. Regulación hipofisiaria de la secreción de hormona de crecimiento. En: Calzada-León R, ed. El sistema de la hormona de crecimiento. Encuentro Serono México 1995:23-30.

9. Karin M, Castrillo JL, Theill LE. Growth hormone gene regulation: a paradigm for a cell-type-specific gene activation. Trends in genetics 1990;6:92-96.

10. Casonueva F. Physiology of growth hormone secretion and action. Endocrinol Metab Clin North Am 1992;21:483- 517.

11. Tannenbaum GS, Ling N. The interrelationship of growth hormone (hormona de crecimiento) releasing factor and somatostatin in generation of the ultradian rhythm of hormona de crecimiento secretion. Endocrinology 1984;115:1952.

12. Devesa J. hormona de crecimiento y somatomedinas: acciones biológicas y control de su secreción. En: Treguerres JAF, ed. Fisiología endocrina. Madrid: Evdema, 1989:141-178.

13. Mendoza-Morfin F. Neuropéptidos y regulación hipotalámica de GHRH y somatostina. En: Calzada-León R, ed. El sistema de hormona de crecimiento. Encuentro Serono México 1995:13-22.

14. Hintz RL. Somatomedines. En: Barness LA, ed. Advances in pediatrics. Vol 68. Chicago: Year Book Med Pub, 1984:293.

15. Nilsson A, Isgaard J, Lindahl A, Dahlstrom A. Regulation by growth hormone of number of chondrocytes containing IGF-I in rat growth plate. Science 1986;233:571-74.

16. Lindahl A, Isgaard J, Carlsson L, Isaksson OGP. Differential effects of growth hormone and insulin-like growth factor l on colony formation of epiphyseal chondrocytes in suspension culture in rats of different ages. Endocrinology 1987;121:1061- 1069.

17. Isgaard J, Nilsson A, Isaksson O, Moller C, Nortsted G. Regulation of IGF-I, mRNA in rat growth plate by growth hormone. Program of the 69 annual meeting of the Endocrine Society, Indianapolis (Abstract 305) 1987.

18. Arilla E, Rodríguez-Sánchez MN, Fragoso J, Barrios V. Avances en el conocimiento de la estructura molecular y mecanismo de acción de la GH. En: Hernández Rodríguez M, ed. hormona de crecimiento. Madrid: Díaz de Santos, Madrid 1988.

19. Hintz RL. Bases fisiológicas del crecimiento. En: Hintz RL, Rossenfeld RG, ed. Trastornos del crecimiento. Barcelona: Ancora SA, 1987:l-ll.

20. Von Harnack GA, Tanner JM, Whitehouse RH. Catch-up growth in hei hormona de crecimientot and skeletal maturity in children on long-term treatment for hypotyroidism. Z Kinderheild 1972;112:1.

21. Katakami H, Dorns TR, Frohman LD. Decreased hypothalamic growth hormone releasing hormone content and pituitary responsiveness in hypothyroidism. J Clin Invest 1986;77:1704-1709.

22. Dau hormona de crecimientoaday WH. Hormonal regulation of growth. Clin Endocrinol Metab 1977;6:117-135.

23. Tanner JM, Whitehouse RH, Hu hormona de crecimientoes PCR. Relative importance of growth hormone and sex steroids for the growth at puberty of trunk length and muscle width in growth hormone-deficient children. J Pediatr 1976;89:1000.

24. Tannner JM. Normal growth and techniques of growth assessment. En: Savage MO, Randall RA, ed. Growth disorders. Philadelphia: Saunders Co., 1986:411-452.

25. Penrose LS. Some recent trends in human genetics. Caryologia 1954;61 (Suppl): 521.

26. Tanner JM. Cath-up growth in man. Br Med Bull 1981;37:233-238.

27. Carter CO, Marshall WA. The genetics of adult stature. En: Falkner F, Tanner JM, ed. Human growth.1, London: Balliere Tindall, 1978:1299-1306.

28. Zadik Z, Chalew SA, Raiti S, Kowarski AA. Do short children secrete insufficient growth hormone? Pediatrics 1985;76:355-360.

29. Garcia Morales L. Abordaje diagnóstico en el paciente con sospecha de talla baja familiar. En: Calzada-León R, ed. Variantes normales del crecimiento. ll Encuentro Iberoamericano de Crecimiento, México. Pisa-Novo-Nordisk 1995:173-183.

30. Groll A. Short stature as a primary manifestation of coeliac disease. Lancet 1980;2:1097.

31. Clark RN. Congenital dysplasias and dwarfism. Pediatr Rev 1990;12:149-159.

32. Pombo-Arias M. Abordaje diagnóstico en el retraso constitucional del crecimiento. En: Calzada-León R, ed. Variantes normales del crecimiento. ll Encuentro Iberoamericano de crecimiento. México. Pisa-Novo Nordisk 1996:271-282.

33. Calzada-León R, Garcia-Flores M, González-Paz A. Retraso constitucional del crecimiento. En: Calzada- León R, ed. Variantes normales del crecimiento. ll Encuentro Iberoamericano de crecimiento. México. Pisa-Novo Nordisk 1996:219-239.

34. Heinze HJ, Bercu BB. Short stature and the patterns of growth hormone secretion. Endocrinologist 1993;3:331-343.

35. Kerrigan JR, Martha PM, Veldhuis JD, Blizzard RM, Ragol AD. Altered growth hormone secretory dinamics in prepubertal males with constitutional delay of growth. Pediatr Res 1993;33:278-283.

36. Rudman, Kutner MH, Blakston RD, Patterson JH. Children with normal-variant short stature: treatment with human growth hormone for six months. N Engl J Med 1981;30513:123-129.

37. Gordon M, Croothamel C, Post EM, Richman RA. Psychosocial aspects of constitutional short stature: social competence, behavior problems, self-esteam and family functioning. J Pediatr 1982;101:477- 480.

38. Dorantes-Alvarez LM. Tratamiento del niño con talla baja familiar. En: Calzada-León R, ed. El sistema de la hormona de crecimiento. l Encuentro Iberoamericano de crecimiento, México. Encuentro Serono México 1995;229-235.

39. Geller J. Oxandrolone effect on growth and bone in idiopathic growth failure. Acta Endocrinol 1968;59:307-316.

40. Hockberg Z, Korman S. Oxandrolone therapy in boys of short stature. J Pediatr Endocrinol 1987;2:115-120.

41. Strickland AL. Long-term result of treatment with low dose fluoximesterone in constitutional delay of growth and puberty and in genetic short stature. Pediatrics 1993;91:716-720.

42. Pintor C, Cella SG, Cord AR, Locatelli V, Piggioni R. Clonidine accelerates growth in children with impaired growth hormone secretion. Lancet 1985;1:1482-1484.

43. Dorantes-Alvarez L, Coyote-Estrada N, Parra-Paredes S, Garcia-Morales L, Metlich-Medlich B. Efectos de la administración de clonidina en niños con talla baja familiar y retardo constitucional del crecimiento. Bol Med Hosp Infant Mex 1992;49:422-426.

44. Genentech Collaborative Study group. Idiopathic short stature: results of a one-year controlled study of human growth hormone treatment. J Pediatr 1989;115:713-719.

45. Hopwood N, Hintz R, Gertner J et al. Growth response of children with non-growth hormone deficiency and marked short stature during three years of growth hormone therapy. J Pediatr 1993;123:215-222.

46. Dorantes-Alvarez L, Garcia Morales L. Evaluación del tratamiento de la talla baja constitucional con hormona de crecimiento obtenida de células de mamífero. Bol Med Hosp Infant Mex 1995;52>:431-434.

47. Hindmarsh PC, Brooks CGD. Final hei hormona de crecimiento of short normal children treated with growth hormone. Lancet 1996;348:13-16.

48. Brooke OG. Food and the fetus and neonate. Proc Nutr Soc 1980;39:17

49. Hack M, Fanaroff AA: The outcome of growth failure associated with preterm birth. Clin Obstet Gynecol 27:647- 1984.

50. Chernausek SD, Breen T, Frank GR. Linear growth in response to growth hormone treatment in children with short stature associated with intrauterine growth retardation: The National Cooperative Growth Study Experience. J Pediatr 1996;128:522-527.

51. Parra-Covarrubias A, Dorantes-Alvarez L, Barron-Uribe C, Perez-Pastén E, Robles-Valdéz C. ed. Los aspectos éticos del uso de la hormona de crecimiento humana biosintética. México: Academia Mexicana de Pediatría, 1993:17-37.

52. Törshoff B, Schaefer F, Mehls D. Disturbance of growth hormone-insulin-like growth factor axis in uremia. Pediatr Nephrol 1990;4:654-662.

53. Lippe B, Fine RN, Hoch UH, Sherman BM. Accelerated growth following treatment of children with chronic renal failure with recombinant human growth hormone: a preliminary report. Acta Paediatr Scand 1988;343 (suppl):127-131.

54. Tönshoff B, Mehls OHeinrich U, Blum WF, Rankg MB, Schaver A. Growth-stimulating effect of recombinant human growth hormone in children with end-stage renal disease. One year experience. J Pediatr 1990;116:561-566

55. Johanson G, Sietnieks A, Janssen F, Proesman SW. Recombinant human growth hormone treatment in short children with chronic renal disease, before transplantation or with functioning renal transplant: an interin report on five European studies. Acta Paediatr Scand 1990;370 (Suppl):36-42

56. Werther GA, Matthews R, Burger HG, Herlington AC. Deficiency of nonsupressible insulin-like activity in children with thalassemia major. Arch Dis Child 1981;56:855

57. Werther GA, Matthews RN, Burger HG, Herlington AC. Lack of response of nonsupressible insulin-like activity to short-term administration of human growth hormone in thalassemia major. J Clin Endocrinol Metab 1981;53:806

58. Richardson V, Dorantes-Alvarez LM. Vitamina D y raquitismo. Part l. Bol Med Hosp Infant Mex 1983;40:417-423

59. Armendarez S, Salamanca F. Hallazgos clínicos y cromosómicos en 74 pacientes con Síndrome de Turner atendidos en un hospital de pediatria. Rev Inv Clin Mex 1977;29:295-304

60. Rosenfeld RG. Update on growth hormone therapy for Turner's syndrome. Acta Paediatr Scand 1989;356 (Suppl):103- 108

61. Dorantes-Alvarez LM, Garcia-Morales L, Coyote-Estrada N. Tratamiento con hormona de crecimiento recombinante en talla baja asociada a Síndrome de Turner. Bol Med Hosp Infant Mex 1995;52:435-438.

62. Altamirano-Bustamante N. Tratamiento de pacientes con Síndrome de Turner con hormona de crecimiento humana biosintética. En: Calzada-León R, ed. El sistema de la hormona de crecimiento. Encuentro Serono México 1995;211-219

63. Ahmed ML, Foot ABM, Savage MO, Lamkin V. Noonan's syndrome: the response to treatment with biosynthetic human growth hormone. Acta Paediatr Scand 1989;356 (Suppl):162

64. Preece MA. Diagnosis and treatment of children with growth hormone deficiency. Clin Endocrinol Metab 1982;11:1-24

65. Raben MS. Treatment of a pituitary dwarf with human growth hormone. J Clin Endocrinol Metab 1958;18:901-903

66. Powell-Jackson J, Weller RO, Kennedy P. Creutzfeldt-Jacob disease after administration of human growth hormone. Lancet 1985;3:244.

67. Gray GL, Baldrige JS, Mc Kwowon KS, Hyneker HL, Chang LN. Periplasmatic production of correctly processed human growth hormone in Escherichia coli;natural and bacterial signal sequences are interchangeable. Gene 1985;39:247-254.

68. Dorantes-Alvarez LM, Parra-Paredes S. Experiencia clínica del tratamiento del enanismo por deficiencia de hormona de crecimiento con somatotropina biosintética. Bol Med Hosp Infant Mex 1989;46:531-536.

69. Dorantes LM. Clinical experience of treatment of growth hormone deficiency with somatrem and recombinant somatropin. Acta Paediatr Scand 1989;349 (Suppl):156.

70. Barron-Uribe C. Tratamiento de la deficiencia de hormona de crecimiento con hormona de crecimiento biosintética. En: Calzada-León R, ed. El sistema de la hormona de crecimiento. Encuentro Serono México 1995;193-209.

71. Picó A, Mauri M, Camara R. Alteraciones del crecimiento en los transtornos de la pubertad. En: Moreno-Esteban B, Tresguerres-Hernández JAF, ed. Retrasos del crecimiento. Madrid: Díaz de Santos SA, 1991: 331-349.

72. Aron DC, Blake J. Glucocorticoides y andrógenos suprarrenales. En: Greenspan FS, Baxter JD, ed. Endocrinología básica y clínica. México: El Manual moderno, 1995:353-400.

73. Jivani SKM, Rayner PHW. Does control influence the growth of diabetic children? Arch Dis Child 1973;48:109.

74. Kuczmarski JR, Flegal KM, Campbell SM, Johnson LC. The national health and nutrition examination surveys 1960-1991. JAMA 1994;272:205-211.

75. Keys A. Seven countries: A multivariate analysis of death and coronary heart disease. Cambridge, Mass: Harvard University Press, 1980.

76. Gonzalez-Barranco J. XXXIV Reunion anual de la Sociedad de Nutrición y Endocrinología. Ixtapa 1994.

77. Dorantes-Alvarez LM, Coyote-Estrada N. El problema de la obesidad infantil. Paidos 1995;2:3-6.

78. Epstein LH, Wing RR, Valoski A. Obesidad infantil. Clin Pediatr Norteam 1985;2:383-402.

79. Anand BK, Brabeck JR. Hypothalamic control of food intake in rats and cats. Yale J Biol Med 1951;24:123-140.

80. Borg PW, Sherwin SR, During JM. Local ventromedial hypothalamus glucopenia triggers contraregulatory hormone release. Diabetes 1995;44:180-185.

81. Ramirez Y, Friedman MI. Dietary hyperphagia in rats: Role of fat, carbohydrate and energy content. Physiol Behav 1990;47:1157-1163.

82. Masuzaki H, Ogama Y, Isse N. Human obese gene expression adipocyte-specific expression and regional differences in the adipose tissue. Diabetes 1995; 44: 855-858.

83. Lindpainter K. Finding an obesity gene. A tale of mice and man. N Engl J Med 1995;10:679-680.

84. Rink TJ. In search of a saciety factor. Nature 1994;372:406-440

85. Barinaga M. Obese protein slims mice. Science 1995;269:475-476.

86. Knittle JL. Adipose tissue development in man. En: Faulkner F, Tanner JM, eds. Human growth,Vol 2: Postnatal growth. New York: Plenum Press, 1978:295-315.

87. Knittle JL. The growth of adipose tissue in children and adolescents. J Clin Invest 1979;63:239.

88. Considine R, Sinha M, Helman M. Serum leptine concentration in normal wei hormona de crecimientot and obese humans. N Engl J Med 1996;334:292-295.

89. Dietz WH. Prevention of childhood obesity. Pediatr Clin North Am 1986:33:823.

90. Pellet PL. Food energy requirements in humans. Am J Clin Nutr 1990;51:711-722.

91. American Dietetic Association. Handbook of clinical dietetics New Haven: Yale University Press, 1981:20.

92. Amatruda JM, Welle S. Obesity. En: Felig P, Baxter JD, ed. Endocrinology and metabolism. 3rd ed. New York: Mc Graw-Hill, 1995:1271-1303.

93. Hoffman BB, Lefkowitz RJ. Catecolaminas y drogas simpaticomiméticas. En: Goodman Guilman A, Rall TW, Nies AS, Taylor P. Las bases farmacológicas de la terapéutica, 8a. ed. Buenos Aires: Ed Médica Panamericana, 1991:196-225.

94. Guy-Grand B, Apfelbaum M, Grepaldi G, Gries A, LefebreP, Turner P. International trial of long term dexfenfluoramine of obesity. Lancet 1989; 2:1142-1148.

95. Mc Tavish D, Heel RC. Dexfenfluoramine: A review of its pharmacological properties and therapeutic potential in obesity. Drugs 1992; 43:713-732.

96. Jack DB. Fi hormona de crecimientoting obesity the Franco-British way. Lancet 1996; 347:1756.